STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
Matthew Herper·
·1 min read
·
0 reactions
·
0 comments
·
16 views
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
Original article
STAT · Matthew Herper
Anonymous · no account needed
Discussion
0 commentsMore from STAT
STAT+: What the pope’s encyclical on AI means for Catholic hospitals, and all of health care
STAT·6
Top ultra-processed food researchers call for sweeping policy change: ‘The system is rigged’
STAT·6
Opinion: The medical-billing AI arms race between providers and insurance
STAT·6
Opinion: The Amish way of health care
STAT·7
Opinion: How the military may be fueling eating disorders in men
STAT·6
STAT+: NIH cuts weakened network primed to respond to outbreaks like Ebola
STAT·10